{"id":"https://openalex.org/W4248865448","doi":"https://doi.org/10.1097/01.cco.0000245316.82391.52","title":"Sorafenib","display_name":"Sorafenib","publication_year":2006,"publication_date":"2006-09-21","ids":{"openalex":"https://openalex.org/W4248865448","doi":"https://doi.org/10.1097/01.cco.0000245316.82391.52","pmid":"https://pubmed.ncbi.nlm.nih.gov/16988583"},"language":"en","primary_location":{"id":"doi:10.1097/01.cco.0000245316.82391.52","doi":"https://doi.org/10.1097/01.cco.0000245316.82391.52","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.cco.0000245316.82391.52","pdf_url":null,"source":{"id":"https://openalex.org/S179395531","display_name":"Current Opinion in Oncology","issn_l":"1040-8746","issn":["1040-8746","1080-8140","1531-703X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113098970","display_name":"Olwen Mary Hahn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olwen Hahn","raw_affiliation_strings":["Section of Hematology/Oncology, Department of Medicine, University of Chicago, Illinois 60637, USA","Conflict of Interest: Dr Stadler has received payment to conduct clinical trials and honoraria and consulting fees from Bayer-Onyx","Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology/Oncology, Department of Medicine, University of Chicago, Illinois 60637, USA","institution_ids":["https://openalex.org/I40347166"]},{"raw_affiliation_string":"Conflict of Interest: Dr Stadler has received payment to conduct clinical trials and honoraria and consulting fees from Bayer-Onyx","institution_ids":[]},{"raw_affiliation_string":"Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, Illinois, USA","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088131964","display_name":"Walter Michael Stadler","orcid":"https://orcid.org/0000-0002-0435-2527","observed_orcids":["https://orcid.org/0000-0002-0435-2527"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Walter Stadler","raw_affiliation_strings":["Conflict of Interest: Dr Stadler has received payment to conduct clinical trials and honoraria and consulting fees from Bayer-Onyx","Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, Illinois, USA","to Walter Stadler, MD, FACP, Professor, Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, Illinois 60637, USA Tel: +1 773 702 4150; fax: +1 773 702 3163; e-mail: [email\u00a0protected]","e-mail: [email\u00a0protected]","fax: +1 773 702 3163","to Walter Stadler, MD, FACP, Professor, Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, Illinois 60637, USA Tel: +1 773 702 4150"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Conflict of Interest: Dr Stadler has received payment to conduct clinical trials and honoraria and consulting fees from Bayer-Onyx","institution_ids":[]},{"raw_affiliation_string":"Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, Illinois, USA","institution_ids":["https://openalex.org/I40347166"]},{"raw_affiliation_string":"to Walter Stadler, MD, FACP, Professor, Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, Illinois 60637, USA Tel: +1 773 702 4150; fax: +1 773 702 3163; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I40347166"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 773 702 3163","institution_ids":[]},{"raw_affiliation_string":"to Walter Stadler, MD, FACP, Professor, Sections of Hematology/Oncology and Urology, Departments of Medicine and Surgery, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, Illinois 60637, USA Tel: +1 773 702 4150","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5088131964"],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":1.4594,"has_fulltext":false,"cited_by_count":75,"citation_normalized_percentile":{"value":0.80068337,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"18","issue":"6","first_page":"615","last_page":"621"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.9279999732971191},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8569999933242798},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.8360000252723694},{"id":"https://openalex.org/keywords/raf-kinase-inhibitors","display_name":"Raf kinase inhibitor","score":0.7730000019073486},{"id":"https://openalex.org/keywords/vegfr","display_name":"VEGFR","score":0.8679999709129333},{"id":"https://openalex.org/keywords/pdgfr","display_name":"PDGFR","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9449999928474426},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.6010000109672546},{"id":"https://openalex.org/keywords/hand-foot-syndrome","display_name":"hand-foot syndrome","score":0.7979999780654907},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8899999856948853},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.7850000262260437},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.753000020980835},{"id":"https://openalex.org/keywords/locally-advanced-renal-cancer","display_name":"locally advanced renal cancer","score":0.5929999947547913}],"concepts":[{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.9844977855682373},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9341821670532227},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6329475045204163},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6189101934432983},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6046428680419922},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5718216896057129},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.4883958697319031},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.463636577129364},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.44527512788772583},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.43545228242874146},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.11729922890663147}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D040262","descriptor_name":"Receptors, Vascular Endothelial Growth Factor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.cco.0000245316.82391.52","doi":"https://doi.org/10.1097/01.cco.0000245316.82391.52","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.cco.0000245316.82391.52","pdf_url":null,"source":{"id":"https://openalex.org/S179395531","display_name":"Current Opinion in Oncology","issn_l":"1040-8746","issn":["1040-8746","1080-8140","1531-703X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in Oncology","raw_type":"journal-article"},{"id":"pmid:16988583","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16988583","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W65325140","https://openalex.org/W1967835627","https://openalex.org/W1978173977","https://openalex.org/W1996283150","https://openalex.org/W2000292756","https://openalex.org/W2010890298","https://openalex.org/W2018348203","https://openalex.org/W2033529092","https://openalex.org/W2049171090","https://openalex.org/W2052550764","https://openalex.org/W2053146576","https://openalex.org/W2090359261","https://openalex.org/W2099259685","https://openalex.org/W2099938880","https://openalex.org/W2116177733","https://openalex.org/W2123421036","https://openalex.org/W2139248078","https://openalex.org/W2140765540","https://openalex.org/W2142943611","https://openalex.org/W2145537131","https://openalex.org/W2147718842","https://openalex.org/W2149026055","https://openalex.org/W2159594827","https://openalex.org/W2166271687","https://openalex.org/W2216142253","https://openalex.org/W2241551449","https://openalex.org/W2241660038","https://openalex.org/W2305352133","https://openalex.org/W2331201327","https://openalex.org/W2336431470","https://openalex.org/W2517521286","https://openalex.org/W2539182848","https://openalex.org/W2584142366","https://openalex.org/W2599442252"],"related_works":["https://openalex.org/W2372282150","https://openalex.org/W2147211465","https://openalex.org/W2167161551","https://openalex.org/W2097415899","https://openalex.org/W2090485811","https://openalex.org/W7095495438","https://openalex.org/W2060370107","https://openalex.org/W2149026055","https://openalex.org/W2151507583","https://openalex.org/W2047964609"],"abstract_inverted_index":{"PURPOSE":[0],"OF":[1],"REVIEW:":[2],"Sorafenib":[3,36],"is":[4,20],"an":[5,41],"oral,":[6],"multikinase":[7],"inhibitor":[8,42],"that":[9,79,125,184],"was":[10,37,120],"recently":[11],"approved":[12],"for":[13,101],"use":[14],"in":[15,24,30,130,143,165],"metastatic":[16,133],"renal":[17,27,134,169],"cancer.":[18,170],"It":[19],"currently":[21],"undergoing":[22],"investigation":[23],"locally":[25],"advanced":[26],"cancer":[28],"and":[29,60,73,162,181],"other":[31],"tumor":[32,95],"types.":[33],"RECENT":[34],"FINDINGS:":[35],"initially":[38],"developed":[39],"as":[40,82,86],"of":[43,160,168,177,189],"Raf":[44],"kinase;":[45],"however,":[46],"it":[47],"has":[48],"broad":[49],"spectrum":[50],"activity":[51],"against":[52],"multiple":[53],"tyrosine":[54],"kinases,":[55],"including":[56],"angiogenic":[57],"factors":[58],"VEGFR":[59],"PDGFR.":[61],"Common":[62],"toxicities":[63],"experienced":[64,89],"with":[65,132],"sorafenib":[66,80,126,161],"include":[67],"hypertension,":[68],"hand-foot":[69],"syndrome,":[70],"rash,":[71],"diarrhea":[72],"fatigue.":[74],"Early":[75],"clinical":[76,112,158,178],"trials":[77],"suggested":[78],"acts":[81],"a":[83,111,114,144],"cytostatic":[84],"agent,":[85],"many":[87],"patients":[88,131],"prolonged":[90],"disease":[91],"stabilization":[92],"but":[93],"insufficient":[94],"shrinkage":[96],"to":[97,186],"meet":[98],"RECIST":[99],"criteria":[100],"response.":[102],"To":[103],"assess":[104],"whether":[105],"sorafenib's":[106],"growth":[107],"inhibition":[108],"translated":[109],"into":[110],"benefit,":[113],"phase":[115,138,147],"II":[116,139],"randomized":[117],"discontinuation":[118],"trial":[119,123,179],"designed.":[121],"This":[122],"demonstrated":[124],"increased":[127],"progression-free":[128],"survival":[129],"cell":[135],"cancer;":[136],"the":[137,157,166,187],"data":[140],"were":[141],"confirmed":[142],"large":[145],"international":[146],"III":[148],"trial.":[149],"SUMMARY:":[150],"In":[151],"this":[152],"review,":[153],"we":[154,172],"will":[155,173],"discuss":[156],"development":[159,183,188],"its":[163],"role":[164],"treatment":[167],"Additionally,":[171],"highlight":[174],"critical":[175],"methods":[176],"design":[180],"biomarker":[182],"contribute":[185],"sorafenib.":[190]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-05-12T00:00:00"}